Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 17/20 | 0.67 |
| ▸ | DDB1 | Q16531 | 9/20 | 0.51 |
| ▸ | AR | P10275 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.49 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.49 |
| ▸ | CDK9 | P50750 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29927364 | 1.00 | CRBN (0.67) | CRBNDDB1ARALDH1A1CHRM2 | |
| SCHEMBL20234536 | 1.00 | CRBN (0.67) | CRBNDDB1ARALDH1A1CHRM2 | |
| SCHEMBL29132171 | 1.00 | CRBN (0.67) | CRBNDDB1ARALDH1A1CHRM2 | |
| SCHEMBL29927985 | 0.96 | CRBN (0.65) | CRBNDDB1ARALDH1A1CHRM2 | |
| SCHEMBL29132298 | 0.96 | CRBN (0.65) | CRBNDDB1ARALDH1A1CHRM2 | |
| SCHEMBL29927274 | 0.96 | CRBN (0.65) | CRBNDDB1ARALDH1A1CHRM2 | |
| SCHEMBL29132341 | 0.96 | CRBN (0.65) | CRBNDDB1ARALDH1A1CHRM2 | |
| SCHEMBL31390660 | 0.94 | CRBN (0.68) | CRBNDDB1ARALDH1A1CHRM2 | |
| SCHEMBL31390661 | 0.94 | CRBN (0.68) | CRBNDDB1ARALDH1A1CHRM2 | |
| SCHEMBL20231895 | 0.94 | CRBN (0.70) | CRBNDDB1ARALDH1A1CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230137175-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BRUTON'S TYROSINE KINASE | ENDOTARGET INC. | 2023-05-04 | — | — | US | disclosed |
| US-20230137175-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BRUTON'S TYROSINE KINASE | ENDOTARGET INC. | 2023-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230137175-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BRUTON'S TYROSINE KINASE | BTK, BCL9, CRBN | CRBN 3/4885DDB1 362/4885AR 3307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.